Literature DB >> 20943696

Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.

Michael T White1, Jamie T Griffin, Eleanor M Riley, Chris J Drakeley, Ann M Moorman, Peter Odada Sumba, James W Kazura, Azra C Ghani, Chandy C John.   

Abstract

Antibodies to the pre-erythrocytic antigens, circumsporozoite protein (CSP), thrombospondin-related adhesive protein (TRAP) and liver-stage antigen 1, have been measured in field studies of semi-immune adults and shown to correlate with protection from Plasmodium falciparum infection. A mathematical model is formulated to estimate the probability of sporozoite infection as a function of antibody titres to multiple pre-erythrocytic antigens. The variation in antibody titres from field data was used to estimate the relationship between the probability of P. falciparum infection per infectious mosquito bite and antibody titre. Using this relationship, we predict the effect of vaccinations that boost baseline CSP or TRAP antibody titres. Assuming the estimated relationship applies to vaccine-induced antibody titres, then single-component CSP or TRAP antibody-mediated pre-erythrocytic vaccines are likely to provide partial protection from infection, with vaccine efficacy of approximately 50 per cent depending on the magnitude of the vaccine-induced boost to antibody titres. It is possible that the addition of a TRAP component to a CSP-based vaccine such as RTS,S would provide an increase in infection-blocking efficacy of approximately 25 per cent should the problem of immunological interference between antigens be overcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943696      PMCID: PMC3061132          DOI: 10.1098/rspb.2010.1697

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  49 in total

1.  Expression of thrombospondin-related anonymous protein in Plasmodium falciparum sporozoites.

Authors:  G Cowan; S Krishna; A Crisanti; K Robson
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

Review 2.  Immune responses to sporozoite antigens and their relationship to naturally acquired immunity to malaria.

Authors:  B M Greenwood
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi.

Authors:  J C Beier; J R Davis; J A Vaughan; B H Noden; M S Beier
Journal:  Am J Trop Med Hyg       Date:  1991-05       Impact factor: 2.345

4.  Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children.

Authors:  E M Riley; S J Allen; S Bennett; P J Thomas; A O'Donnell; S W Lindsay; M F Good; B M Greenwood
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Sep-Oct       Impact factor: 2.184

5.  TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites.

Authors:  A A Sultan; V Thathy; U Frevert; K J Robson; A Crisanti; V Nussenzweig; R S Nussenzweig; R Ménard
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

6.  A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge.

Authors:  S Chatterjee; M Wery; P Sharma; V S Chauhan
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 7.  Antisporozoite vaccine for malaria: experimental basis and current status.

Authors:  R S Nussenzweig; V Nussenzweig
Journal:  Rev Infect Dis       Date:  1989 May-Jun

8.  Fine structure of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro.

Authors:  J F Meis; P J Rijntjes; J P Verhave; T Ponnudurai; M R Hollingdale; J E Smith; R E Sinden; P H Jap; J H Meuwissen; S H Yap
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

9.  Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya.

Authors:  J C Beier; C N Oster; F K Onyango; J D Bales; J A Sherwood; P V Perkins; D K Chumo; D V Koech; R E Whitmire; C R Roberts
Journal:  Am J Trop Med Hyg       Date:  1994-05       Impact factor: 2.345

10.  Ingestion of Plasmodium falciparum sporozoites during transmission by anopheline mosquitoes.

Authors:  M S Beier; J R Davis; C B Pumpuni; B H Noden; J C Beier
Journal:  Am J Trop Med Hyg       Date:  1992-08       Impact factor: 2.345

View more
  11 in total

Review 1.  The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma.

Authors:  Ann M Moormann; Cynthia J Snider; Kiprotich Chelimo
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

2.  Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.

Authors:  Aneesh Vijayan; Carmen E Gómez; Diego A Espinosa; Alan G Goodman; Lucas Sanchez-Sampedro; Carlos Oscar S Sorzano; Fidel Zavala; Mariano Esteban
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

3.  Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.

Authors:  Cate Speake; Alexander Pichugin; Tejram Sahu; Vlad Malkov; Robert Morrison; Ying Pei; Laure Juompan; Neta Milman; Stasya Zarling; Charles Anderson; Sharon Wong-Madden; Jason Wendler; Andrew Ishizuka; Zachary W MacMillen; Valentino Garcia; Stefan H I Kappe; Urszula Krzych; Patrick E Duffy
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

4.  Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.

Authors:  Gustavo Cabral-Miranda; Matthew D Heath; Mona O Mohsen; Ariane C Gomes; Paul Engeroff; Amy Flaxman; Fabiana M S Leoratti; Aadil El-Turabi; Arturo Reyes-Sandoval; Murray A Skinner; Matthias F Kramer; Martin F Bachmann
Journal:  Vaccines (Basel)       Date:  2017-05-02

5.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.

Authors:  Katharine A Collins; Rebecca Snaith; Matthew G Cottingham; Sarah C Gilbert; Adrian V S Hill
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

6.  Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.

Authors:  Camila Tenorio França; Michael T White; Wen-Qiang He; Jessica B Hostetler; Jessica Brewster; Gabriel Frato; Indu Malhotra; Jakub Gruszczyk; Christele Huon; Enmoore Lin; Benson Kiniboro; Anjali Yadava; Peter Siba; Mary R Galinski; Julie Healer; Chetan Chitnis; Alan F Cowman; Eizo Takashima; Takafumi Tsuboi; Wai-Hong Tham; Rick M Fairhurst; Julian C Rayner; Christopher L King; Ivo Mueller
Journal:  Elife       Date:  2017-09-26       Impact factor: 8.140

7.  Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.

Authors:  Michael T White; Robert Verity; Jamie T Griffin; Kwaku Poku Asante; Seth Owusu-Agyei; Brian Greenwood; Chris Drakeley; Samwel Gesase; John Lusingu; Daniel Ansong; Samuel Adjei; Tsiri Agbenyega; Bernhards Ogutu; Lucas Otieno; Walter Otieno; Selidji T Agnandji; Bertrand Lell; Peter Kremsner; Irving Hoffman; Francis Martinson; Portia Kamthunzu; Halidou Tinto; Innocent Valea; Hermann Sorgho; Martina Oneko; Kephas Otieno; Mary J Hamel; Nahya Salim; Ali Mtoro; Salim Abdulla; Pedro Aide; Jahit Sacarlal; John J Aponte; Patricia Njuguna; Kevin Marsh; Philip Bejon; Eleanor M Riley; Azra C Ghani
Journal:  Lancet Infect Dis       Date:  2015-09-02       Impact factor: 25.071

8.  The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum.

Authors:  Michael T White; Jamie T Griffin; Azra C Ghani
Journal:  Malar J       Date:  2013-08-08       Impact factor: 2.979

9.  A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.

Authors:  Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Kalifa Bojang; John Lusingu; Nahya Salim; Salim Abdulla; Nekoye Otsyula; Selidji T Agnandji; Bertrand Lell; Kwaku Poku Asante; Seth Owusu-Agyei; Emmanuel Mahama; Tsiri Agbenyega; Daniel Ansong; Jahit Sacarlal; John J Aponte; Azra C Ghani
Journal:  BMC Med       Date:  2014-07-10       Impact factor: 8.775

Review 10.  malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.

Authors: 
Journal:  PLoS Med       Date:  2017-11-30       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.